The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19
Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatm...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
2020-12-01
|
| Series: | Сеченовский вестник |
| Subjects: | |
| Online Access: | https://www.sechenovmedj.com/jour/article/view/239 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849248534763667456 |
|---|---|
| author | Yu. N. Belenkov I. V. Menshikova I. S. Ilgisonis Yu. I. Naimann Yu. V. Pak I. R. Kolosova A. S. Rakovskaya |
| author_facet | Yu. N. Belenkov I. V. Menshikova I. S. Ilgisonis Yu. I. Naimann Yu. V. Pak I. R. Kolosova A. S. Rakovskaya |
| author_sort | Yu. N. Belenkov |
| collection | DOAJ |
| description | Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatment of the patients with COVID-19 in recommended by Russian Ministry of Health doses in real practice.Methods. 132 patients (62 men and 70 women of average age 59.2 ± 9.3 years), 59% of whom had cardiovascular comorbidities, were included in prospective сohort study. 112 patients took HCH + AZM (group 1) and 20 patients took other medications without potential cardiotoxicity (group 2). At the admission to the hospital and after 5–7 days of the treatment corrected QT interval was calculated, new rhythm and conduction disorders, other side effects and hospital mortality have been registering. Relative risk (RR) and 95% confidence interval (CI) were calculated. Results. Elongation of corrected QT-interval within the normal range was registered in 22.3% of patients in group 1 and in 15% — in group 2. An increase in the QT length to the upper limit of the norm (480 msec) was observed in 1.8% of patients in group 1. There were no statistically significant differences between the groups in the number of patients with prolonged QT interval (RR = 1.488, 95% CI: 0.496–4.466, р = 0.478). The occurrence of new arrhythmias, conduction disturbances and allergic reactions was not recorded. Tolerability of combination HCH + AZM was satisfactory in the majority of patients. The hospital mortality in group 1 was 1.8%, in group 2 — 5% without statistically significant difference (p = 0.374). Conclusion. A combination of HCL + AZM according to the scheme recommended by the Ministry of Health of the Russian Federation for the treatment of the patients with COVID-19 and cardiovascular comorbidity in inpatient conditions is safe. |
| format | Article |
| id | doaj-art-0ad44a0e5eaa4b2bbb2ea2a01958495a |
| institution | Kabale University |
| issn | 2218-7332 2658-3348 |
| language | Russian |
| publishDate | 2020-12-01 |
| publisher | Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) |
| record_format | Article |
| series | Сеченовский вестник |
| spelling | doaj-art-0ad44a0e5eaa4b2bbb2ea2a01958495a2025-08-20T03:57:51ZrusFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Сеченовский вестник2218-73322658-33482020-12-01112293910.47093/2218-7332.2020.11.2.29-39137The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19Yu. N. Belenkov0I. V. Menshikova1I. S. Ilgisonis2Yu. I. Naimann3Yu. V. Pak4I. R. Kolosova5A. S. Rakovskaya6Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatment of the patients with COVID-19 in recommended by Russian Ministry of Health doses in real practice.Methods. 132 patients (62 men and 70 women of average age 59.2 ± 9.3 years), 59% of whom had cardiovascular comorbidities, were included in prospective сohort study. 112 patients took HCH + AZM (group 1) and 20 patients took other medications without potential cardiotoxicity (group 2). At the admission to the hospital and after 5–7 days of the treatment corrected QT interval was calculated, new rhythm and conduction disorders, other side effects and hospital mortality have been registering. Relative risk (RR) and 95% confidence interval (CI) were calculated. Results. Elongation of corrected QT-interval within the normal range was registered in 22.3% of patients in group 1 and in 15% — in group 2. An increase in the QT length to the upper limit of the norm (480 msec) was observed in 1.8% of patients in group 1. There were no statistically significant differences between the groups in the number of patients with prolonged QT interval (RR = 1.488, 95% CI: 0.496–4.466, р = 0.478). The occurrence of new arrhythmias, conduction disturbances and allergic reactions was not recorded. Tolerability of combination HCH + AZM was satisfactory in the majority of patients. The hospital mortality in group 1 was 1.8%, in group 2 — 5% without statistically significant difference (p = 0.374). Conclusion. A combination of HCL + AZM according to the scheme recommended by the Ministry of Health of the Russian Federation for the treatment of the patients with COVID-19 and cardiovascular comorbidity in inpatient conditions is safe.https://www.sechenovmedj.com/jour/article/view/239novel coronavirus infectioncovid-19hydroxychloroquinecardiovascular complications |
| spellingShingle | Yu. N. Belenkov I. V. Menshikova I. S. Ilgisonis Yu. I. Naimann Yu. V. Pak I. R. Kolosova A. S. Rakovskaya The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 Сеченовский вестник novel coronavirus infection covid-19 hydroxychloroquine cardiovascular complications |
| title | The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 |
| title_full | The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 |
| title_fullStr | The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 |
| title_full_unstemmed | The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 |
| title_short | The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19 |
| title_sort | study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with covid 19 |
| topic | novel coronavirus infection covid-19 hydroxychloroquine cardiovascular complications |
| url | https://www.sechenovmedj.com/jour/article/view/239 |
| work_keys_str_mv | AT yunbelenkov thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT ivmenshikova thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT isilgisonis thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT yuinaimann thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT yuvpak thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT irkolosova thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT asrakovskaya thestudyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT yunbelenkov studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT ivmenshikova studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT isilgisonis studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT yuinaimann studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT yuvpak studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT irkolosova studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 AT asrakovskaya studyofcardiotoxicityofhydroxychloroquineandazithromycinecombinationinhospitalizedpatientswithcovid19 |